S&P 500   3,625.75 (-0.27%)
DOW   29,913.03 (-0.44%)
QQQ   295.83 (+0.46%)
AAPL   116.12 (+0.82%)
MSFT   213.38 (-0.22%)
FB   274.20 (-0.98%)
GOOGL   1,757.91 (-0.34%)
AMZN   3,182.76 (+2.08%)
TSLA   561.61 (+1.12%)
NVDA   528.29 (+1.93%)
BABA   277.83 (-0.76%)
CGC   26.79 (-0.67%)
GE   10.49 (+0.38%)
MU   62.92 (-1.61%)
AMD   86.44 (+1.61%)
T   28.98 (-0.86%)
NIO   52.83 (-1.27%)
F   9.10 (-3.70%)
ACB   8.63 (-6.50%)
NFLX   481.72 (-0.24%)
GILD   59.63 (-1.03%)
BA   217.92 (-0.26%)
DIS   147.94 (-2.34%)
S&P 500   3,625.75 (-0.27%)
DOW   29,913.03 (-0.44%)
QQQ   295.83 (+0.46%)
AAPL   116.12 (+0.82%)
MSFT   213.38 (-0.22%)
FB   274.20 (-0.98%)
GOOGL   1,757.91 (-0.34%)
AMZN   3,182.76 (+2.08%)
TSLA   561.61 (+1.12%)
NVDA   528.29 (+1.93%)
BABA   277.83 (-0.76%)
CGC   26.79 (-0.67%)
GE   10.49 (+0.38%)
MU   62.92 (-1.61%)
AMD   86.44 (+1.61%)
T   28.98 (-0.86%)
NIO   52.83 (-1.27%)
F   9.10 (-3.70%)
ACB   8.63 (-6.50%)
NFLX   481.72 (-0.24%)
GILD   59.63 (-1.03%)
BA   217.92 (-0.26%)
DIS   147.94 (-2.34%)
S&P 500   3,625.75 (-0.27%)
DOW   29,913.03 (-0.44%)
QQQ   295.83 (+0.46%)
AAPL   116.12 (+0.82%)
MSFT   213.38 (-0.22%)
FB   274.20 (-0.98%)
GOOGL   1,757.91 (-0.34%)
AMZN   3,182.76 (+2.08%)
TSLA   561.61 (+1.12%)
NVDA   528.29 (+1.93%)
BABA   277.83 (-0.76%)
CGC   26.79 (-0.67%)
GE   10.49 (+0.38%)
MU   62.92 (-1.61%)
AMD   86.44 (+1.61%)
T   28.98 (-0.86%)
NIO   52.83 (-1.27%)
F   9.10 (-3.70%)
ACB   8.63 (-6.50%)
NFLX   481.72 (-0.24%)
GILD   59.63 (-1.03%)
BA   217.92 (-0.26%)
DIS   147.94 (-2.34%)
S&P 500   3,625.75 (-0.27%)
DOW   29,913.03 (-0.44%)
QQQ   295.83 (+0.46%)
AAPL   116.12 (+0.82%)
MSFT   213.38 (-0.22%)
FB   274.20 (-0.98%)
GOOGL   1,757.91 (-0.34%)
AMZN   3,182.76 (+2.08%)
TSLA   561.61 (+1.12%)
NVDA   528.29 (+1.93%)
BABA   277.83 (-0.76%)
CGC   26.79 (-0.67%)
GE   10.49 (+0.38%)
MU   62.92 (-1.61%)
AMD   86.44 (+1.61%)
T   28.98 (-0.86%)
NIO   52.83 (-1.27%)
F   9.10 (-3.70%)
ACB   8.63 (-6.50%)
NFLX   481.72 (-0.24%)
GILD   59.63 (-1.03%)
BA   217.92 (-0.26%)
DIS   147.94 (-2.34%)
Log in
NASDAQ:SLGL

Sol-Gel Technologies Stock Forecast, Price & News

$8.37
+0.33 (+4.10 %)
(As of 11/25/2020 10:21 AM ET)
Add
Compare
Today's Range
$8.28
Now: $8.37▼
$8.37
50-Day Range
$7.14
MA: $8.07▼
$8.69
52-Week Range
$5.00
Now: $8.37▼
$21.00
Volume400 shs
Average Volume39,542 shs
Market Capitalization$170.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, which has completed Phase II clinical trials for the treatment of acne vulgaris; Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea; SGT-210, a epidermal growth factor receptor inhibitor, which is in development for the treatment of palmoplantar keratoderma and non-melanoma skin cancer; and tapinarof and roflumilast to treat psoriasis and other dermatological indications. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.
Read More
Sol-Gel Technologies logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.16 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLGL
Previous Symbol
CUSIPN/A
CIK1684693
Webwww.sol-gel.com
Phone972-8931-3429
Employees61

Debt

Debt-to-Equity RatioN/A
Current Ratio9.94
Quick Ratio9.94

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.90 million
Price / Sales7.45
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.57 per share
Price / Book3.26

Profitability

EPS (Most Recent Fiscal Year)($1.26)
Net Income$-24,610,000.00
Net Margins-210.73%
Return on Equity-46.18%
Return on Assets-40.10%

Miscellaneous

Outstanding Shares20,390,000
Market Cap$170.66 million
Next Earnings Date3/23/2021 (Estimated)
OptionableNot Optionable
$8.37
+0.33 (+4.10 %)
(As of 11/25/2020 10:21 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SLGL News and Ratings via Email

Sign-up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sol-Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions

How has Sol-Gel Technologies' stock been impacted by Coronavirus?

Sol-Gel Technologies' stock was trading at $8.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SLGL stock has increased by 1.5% and is now trading at $8.37.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Sol-Gel Technologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sol-Gel Technologies.

What stocks does MarketBeat like better than Sol-Gel Technologies?

Wall Street analysts have given Sol-Gel Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sol-Gel Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sol-Gel Technologies' next earnings date?

Sol-Gel Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for Sol-Gel Technologies.

How were Sol-Gel Technologies' earnings last quarter?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) released its quarterly earnings results on Thursday, November, 12th. The company reported ($0.37) EPS for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.09. The firm earned $2.12 million during the quarter, compared to analysts' expectations of $1.93 million. Sol-Gel Technologies had a negative net margin of 210.73% and a negative return on equity of 46.18%.
View Sol-Gel Technologies' earnings history.

What price target have analysts set for SLGL?

4 brokers have issued 12 month price objectives for Sol-Gel Technologies' stock. Their forecasts range from $21.00 to $33.00. On average, they anticipate Sol-Gel Technologies' stock price to reach $25.25 in the next year. This suggests a possible upside of 201.7% from the stock's current price.
View analysts' price targets for Sol-Gel Technologies.

Are investors shorting Sol-Gel Technologies?

Sol-Gel Technologies saw a increase in short interest in October. As of October 15th, there was short interest totaling 125,100 shares, an increase of 26.4% from the September 30th total of 99,000 shares. Based on an average daily volume of 23,800 shares, the days-to-cover ratio is presently 5.3 days. Approximately 1.5% of the company's shares are sold short.
View Sol-Gel Technologies' Short Interest.

Who are some of Sol-Gel Technologies' key competitors?

Some companies that are related to Sol-Gel Technologies include Spectrum Pharmaceuticals (SPPI), BioSpecifics Technologies (BSTC), Akouos (AKUS), ZIOPHARM Oncology (ZIOP), Eagle Pharmaceuticals (EGRX), VBI Vaccines (VBIV), Basilea Pharmaceutica (BPMUF), Chinook Therapeutics (KDNY), Relmada Therapeutics (RLMD), Geron (GERN), SIGA Technologies (SIGA), Organogenesis (ORGO), Mirum Pharmaceuticals (MIRM), IVERIC bio (ISEE) and Flexion Therapeutics (FLXN).
View all competitors.

What other stocks do shareholders of Sol-Gel Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol-Gel Technologies investors own include CorMedix (CRMD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Flexion Therapeutics (FLXN), Iovance Biotherapeutics (IOVA), Marker Therapeutics (MRKR), Teva Pharmaceutical Industries (TEVA), Viking Therapeutics (VKTX), Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP).

Who are Sol-Gel Technologies' key executives?

Sol-Gel Technologies' management team includes the following people:
  • Dr. Alon Seri-Levy, Co-Founder, CEO & Director (Age 59, Pay $746k)
  • Mr. Gilad Mamlok, Chief Financial Officer (Age 52, Pay $501k)
  • Mr. John M. Vieira, U.S. Head of Commercialization (Age 50, Pay $342k)
  • Prof. David Avnir, Co-Founder
  • Mr. Itzik Yosef, Chief Operating Officer (Age 44)
  • Dr. Karine Neimann, VP of Projects & Planning and Chief Chemist (Age 49)

When did Sol-Gel Technologies IPO?

(SLGL) raised $60 million in an initial public offering on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ served as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

What is Sol-Gel Technologies' stock symbol?

Sol-Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

Who are Sol-Gel Technologies' major shareholders?

Sol-Gel Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (4.52%), Raymond James Financial Services Advisors Inc. (0.36%), Raymond James & Associates (0.24%), Morgan Stanley (0.23%) and Jeppson Wealth Management LLC (0.02%).

Which major investors are selling Sol-Gel Technologies stock?

SLGL stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd..

Which major investors are buying Sol-Gel Technologies stock?

SLGL stock was purchased by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc., Morgan Stanley, Raymond James & Associates, and Jeppson Wealth Management LLC.

How do I buy shares of Sol-Gel Technologies?

Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sol-Gel Technologies' stock price today?

One share of SLGL stock can currently be purchased for approximately $8.37.

How big of a company is Sol-Gel Technologies?

Sol-Gel Technologies has a market capitalization of $170.66 million and generates $22.90 million in revenue each year. The company earns $-24,610,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Sol-Gel Technologies employs 61 workers across the globe.

What is Sol-Gel Technologies' official website?

The official website for Sol-Gel Technologies is www.sol-gel.com.

How can I contact Sol-Gel Technologies?

Sol-Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The company can be reached via phone at 972-8931-3429 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.